Claims for Patent: 7,928,290

Summary for Patent: 7,928,290

Title:	Viral capsid fusion peptide expressing plant cells
Abstract:	The present invention provides an improved process for the production of recombinant peptides. In particular, the present invention provides an improved process for the production of recombinant peptides in the form of viral capsid fusion proteins which can be assembled in vivo in plant cell suspension cultures. The invention also includes plasmids, sequences, and plant cells which allow for non-infectious viral capsid fusion peptide production.
Inventor(s):	Rasochova; Lada (San Diego, CA), Dao; Philip Phuoc (San Diego, CA)
Assignee:	Dow AgroSciences LLC (Indianapolis, IN)
Application Number:	11/069,601
Patent Claims:	1. An isolated plant cell comprising a non-infectious nucleic acid comprising a nucleic acid sequence encoding a fusion peptide, wherein the fusion peptide is comprised of at least one heterologous peptide of interest and at least one viral capsid protein, wherein the heterologous peptide is inserted into at least one surface loop of the viral capsid protein, and wherein the nucleic acid is integrated into the genome of the plant cell. 2. The plant cell of claim 1, wherein the fusion peptide, when expressed in the plant cell, assembles in vivo into a virus like particle. 3. The plant cell of claim 1, wherein the antigenic peptide is selected from the group consisting of Seq. ID. Nos. 1-4. 4. The plant cell of claim 1, wherein the nucleic acid sequence is Seq. ID. No. 5. 5. The plant cell of claim 1, wherein the plant cell is Nicotiana tabacum. 6. The plant cell of claim 1, wherein the plant cell is Oryza sativa. 7. The plant cell of claim 1, wherein the nucleic acid further comprises a 3' untranslated region derived from the 3' untranslated region of the genomic nucleic acid sequence encoding the viral capsid protein. 8. The plant cell of claim 7, wherein the 3' untranslated region further comprises an encapsidation signal. 9. The plant cell of claim 1, wherein the viral capsid protein is derived from a virus that displays native trophism for the plant cell host. 10. The plant cell of claim 1, wherein the viral capsid protein is derived from an icosahedral plant virus. 11. The plant cell of claim 10, wherein the icosahedral virus is selected from the group of viruses consisting of Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus. 12. The plant cell of claim 1, wherein the viral capsid protein is derived from a plant virus that is non-trophic to the plant cell. 13. The plant cell of claim 12, wherein the viral capsid protein is derived from an icosahedral plant virus. 14. The plant cell of claim 13, wherein the icosahedral virus is selected from the group of viruses consisting of Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus. 15. The plant cell of claim 1, wherein the plant cell is a cultured cell in a suspension plant cell culture. 16. A process for producing a heterologous peptide comprising: a) providing the isolated plant cell of claim 1; b) expressing the fusion peptide in the plant cell, wherein the plant cells are grown in a suspension plant cell culture in a fermentation process; c) wherein the expression in the plant cell provides for in vivo assembly of the fusion peptide into a virus like particle; and d) isolating the virus like particle. 17. The process of claim 16, wherein the nucleic acid encoding the fusion peptide is operably linked to a promoter sequence and a terminator sequence. 18. The process of claim 17, wherein the nucleic acid further comprises a viral 3'UTR. 19. The process of claim 18, wherein the 3'UTR comprises an encapsidation signal. 20. The process of claim 17, wherein the nucleic acid further comprises an encapsidation signal. 21. The process of claim 16, wherein the viral capsid protein is derived from a virus that does not display native trophism for the plant cell host. 22. The process of claim 16, wherein the viral capsid protein is derived from a virus that displays native trophism for the plant cell host. 23. The process of claim 16, wherein the viral capsid protein is derived from an icosahedral plant virus. 24. The process of claim 23, wherein the icosahedral virus is selected from the group of viruses consisting of Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus. 25. The process of claim 16, wherein the heterologous peptide is an antigenic peptide. 26. The process of claim 25, wherein the antigenic peptide is a Bacillus anthracis peptide. 27. The process of claim 26, wherein the antigenic peptide is selected from the group consisting of Seq. ID. Nos. 1-4. 28. The process of claim 16, wherein the nucleic acid is selected from the group consisting of Seq. ID. Nos. 5-12. 29. The process of claim 16, additionally comprising administering the virus like particle-to an animal as a vaccine. 30. The process of claim 16, wherein the plant cell is a dicot. 31. The process of claim 30, wherein the plant cell is Nicotiana tabacum. 32. The process of claim 16, wherein the plant cell is a monocot. 33. The process of claim 32, wherein the plant cell is Oryza sativa. 34. The process of claim 16, wherein the nucleic acid does not contain viral sequences encoding viral proteins other than the capsid protein.

Details for Patent 7,928,290

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2024-02-27